File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/life13091851
- Scopus: eid_2-s2.0-85172920531
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report
Title | Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report |
---|---|
Authors | |
Keywords | antibody-drug conjugate case reports gastric cancer immune checkpoint inhibitors trastuzumab |
Issue Date | 31-Aug-2023 |
Publisher | MDPI |
Citation | Life, 2023, v. 13, n. 9 How to Cite? |
Abstract | This case report describes the treatment of a patient diagnosed with de novo stage 4 human epidermal growth factor 2 (HER2)-positive gastric adenocarcinoma with enteroblastic differentiation (GAED), a rare and aggressive form of gastric cancer characterized by a tubulopapillary growth pattern and enteroblastic cell lineage markers such as GPC3, SALL4, and alpha fetoprotein. Given the patient’s symptomatic, advanced-stage cancer, treatment objectives were focused on effectively deterring disease progression and ameliorating symptoms throughout the anticipated multiple lines of therapy. Subsequent to standard first- and second-line therapies for HER2-positive metastatic GC, third-line treatment using the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for seven cycles resulted in satisfactory tumor control and well-preserved physical performance and quality of life, with minimal hematologic and pulmonary toxicities. The patient retained acceptable physical performance to receive subsequent lines of therapies, and still showed a tumor marker response to 5L trastuzumab-based chemotherapy. As the tumor was positive for both HER2 and programmed death-ligand 1 (PD-L1) expressions, the selection and sequencing of anti-HER2 and anti-PD-L1 therapies were discussed in relation to the latest U.S. Food and Drug Administration approvals and trial results. |
Persistent Identifier | http://hdl.handle.net/10722/346203 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ngan, Roger Kai Cheong | - |
dc.date.accessioned | 2024-09-12T00:30:49Z | - |
dc.date.available | 2024-09-12T00:30:49Z | - |
dc.date.issued | 2023-08-31 | - |
dc.identifier.citation | Life, 2023, v. 13, n. 9 | - |
dc.identifier.uri | http://hdl.handle.net/10722/346203 | - |
dc.description.abstract | This case report describes the treatment of a patient diagnosed with de novo stage 4 human epidermal growth factor 2 (HER2)-positive gastric adenocarcinoma with enteroblastic differentiation (GAED), a rare and aggressive form of gastric cancer characterized by a tubulopapillary growth pattern and enteroblastic cell lineage markers such as GPC3, SALL4, and alpha fetoprotein. Given the patient’s symptomatic, advanced-stage cancer, treatment objectives were focused on effectively deterring disease progression and ameliorating symptoms throughout the anticipated multiple lines of therapy. Subsequent to standard first- and second-line therapies for HER2-positive metastatic GC, third-line treatment using the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) for seven cycles resulted in satisfactory tumor control and well-preserved physical performance and quality of life, with minimal hematologic and pulmonary toxicities. The patient retained acceptable physical performance to receive subsequent lines of therapies, and still showed a tumor marker response to 5L trastuzumab-based chemotherapy. As the tumor was positive for both HER2 and programmed death-ligand 1 (PD-L1) expressions, the selection and sequencing of anti-HER2 and anti-PD-L1 therapies were discussed in relation to the latest U.S. Food and Drug Administration approvals and trial results. | - |
dc.language | eng | - |
dc.publisher | MDPI | - |
dc.relation.ispartof | Life | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | antibody-drug conjugate | - |
dc.subject | case reports | - |
dc.subject | gastric cancer | - |
dc.subject | immune checkpoint inhibitors | - |
dc.subject | trastuzumab | - |
dc.title | Outcomes of Third-Line Trastuzumab Deruxtecan in a Patient with De Novo Stage 4 HER2-Positive Gastric Adenocarcinoma with Enteroblastic Differentiation: A Case Report | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/life13091851 | - |
dc.identifier.scopus | eid_2-s2.0-85172920531 | - |
dc.identifier.volume | 13 | - |
dc.identifier.issue | 9 | - |
dc.identifier.eissn | 2075-1729 | - |
dc.identifier.issnl | 2075-1729 | - |